Skip to main content

Peer Review reports

From: A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China

Original Submission
9 Nov 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
1 Jan 2023 Reviewed Reviewer Report
2 Mar 2023 Reviewed Reviewer Report
21 Mar 2023 Author responded Author comments - Xinyuan Ding
Resubmission - Version 5
21 Mar 2023 Submitted Manuscript version 5
4 Apr 2023 Reviewed Reviewer Report
14 Apr 2023 Reviewed Reviewer Report
5 May 2023 Author responded Author comments - Xinyuan Ding
Resubmission - Version 6
5 May 2023 Submitted Manuscript version 6
15 May 2023 Reviewed Reviewer Report
26 May 2023 Author responded Author comments - Xinyuan Ding
Resubmission - Version 7
26 May 2023 Submitted Manuscript version 7
Publishing
31 May 2023 Editorially accepted
19 Jul 2023 Article published 10.1186/s12913-023-09628-9

You can find further information about peer review here.

Back to article page